Antibody-dependent cell-mediated cytotoxicity mediated by peripheral blood lymphocytes was studied in patients with systemic lupus erythematosus, polyarteritis nodosa. Sjogren's syndrome, and rheumatoid arthritis. The target cells were chicken erythrocytes coated with rabbit anti-chicken erythrocyte antibody. Antibody-dependent cell-mediated cytotoxic activity was normal in Sjogren's syndrome and rheumatoid arthritis but significantly decreased (P is less than 0.001) in active systemic lupus erythematosus and in two patients with polyarteritis nodosa. A partial regeneration of antibody-dependent cell-mediated cytotoxic activity was obtained by treatment with pronase and DNase followed by overnight incubation. Sera from patients with systemic lupus erythematosus inhibited antibodydependent cell-mediated cytotoxic activity of normal lymphocytes. The inhibitory activity was studied by specific immunoadsorption and sucrose density geadient ultracentrifugation. Removal of IgG but not IgM greatly reduced inhibition. Inhibitory factors were present in 7S and heavier fractions containing IgG. Five systemic lupus erythematosus patients were studied serially to determine if improvement in clinical status could be correlated with a decrease in serum inhibitory factors as studied by inhibition of normal antibody-dependent cell-mediated cytotoxicity. Indeed, a greater serum inhibitory capacity was found in each patient during periods of greater disease activity. A B ST R A C T Antibody-dependent cell-mediated cytotoxicity mediated by peripheral blood lymphocytes was studied in patients with systemic lupus erythematosus, polyarteritis nodosa, Sjogren's syndrome, and rheumatoid arthritis. The target cells were chicken erythrocytes coated with rabbit anti-chicken erythrocyte antibody. Antibody-dependent cell-mediated cytotoxic activity was normal in Sjogren's syndrome and rheumatoid arthritis but significantly decreased (P < 0.001) in active systemic lupus erythematosus and in two patients with polyarteritis nodosa.
A B ST R A C T Antibody-dependent cell-mediated cytotoxicity mediated by peripheral blood lymphocytes was studied in patients with systemic lupus erythematosus, polyarteritis nodosa, Sjogren's syndrome, and rheumatoid arthritis. The target cells were chicken erythrocytes coated with rabbit anti-chicken erythrocyte antibody. Antibody-dependent cell-mediated cytotoxic activity was normal in Sjogren's syndrome and rheumatoid arthritis but significantly decreased (P < 0.001) in active systemic lupus erythematosus and in two patients with polyarteritis nodosa.
A partial regeneration of antibody-dependent cellmediated cytotoxic activity was obtained by treatment with pronase and DNase followed by overnight incubation. Sera from patients with systemic lupus erythematosus inhibited antibody-dependent cell-mediated cytotoxic activity of normal lymphocytes. The inhibitory activity was studied by specific immunoadsorption and sucrose density gradient ultracentrifugation.
Removal of IgG but not IgM greatly reduced inhibition.
Inhibitory factors were present in 7S and heavier fractions containing IgG.
Five systemic lupus erythematosus patients were studied serially to determine if improvement in clinical status could be correlated with a decrease in serum inhibitory factors as studied by inhibition of normal antibody-dependent cell-mediated cytotoxicity. Indeed,
INTRODUCTION
Human peripheral blood lymphoid cells are a heterogenous population consisting of T cells which mediate cellular immunity, B cells which mediate humoral immunity, and a third cell population defined by its ability to lyse antibody-coated target cells (1, 2) . This third population, generally called K or killer cells, may cause -tissue destruction by the mechanism of antibody-dependent cellmediated cytotoxicity (ADCC).1 ADCC has been implicated as an important immunologic defense mechanism against malignancy (3) . Its involvement in renal transplant rejection (4) and in autoimmune tissue destruction (5, 6) has been postulated. Furthermore, ADCC has been proposed as a way of inducing immunologic tolerance, particularly in newborns (7) .
A variety of effector cells mediate ADCC, including monocytes and polymorphonuclear leukocytes (8 . Two patients were on corticosteroids (9 and 20 mg/day). The remaining patients were treated symptomatically.
Diagnosis of PAN was based on the presence of biopsy proven necretizing perivascular infiltration and angiographic demonstration of dilatations in the small to medium sized arteries in the visceral circulation.
Materials. Eagles minimal essential medium (MEM) with 25 mM Hepes buffer (Gibco, New York) supplemented with 5%o heat decomplemented fetal calf sera, (FCS), antibiotic-antimycotic, and 2 mM glutamine was used throughout as the tissue culture medium (TCM). Hanks' balanced salt solution made to 0.05 M, pH 7.4 with Tris-HCl buffer (TH) and containing 2.5%o heat decomplemented FCS (TH-FCS) was employed for in vitro manipulation of CRBC. Sodium-Chromate-51 (200-500 Ci/g) was purchased from New England Nuclear (Boston, Mass.). Goat antihuman IgG and IgM were obtained from Meloy Laboratories Inc., (Springfield, Va.).
Isolation and purification of peripheral blood mononuclear cells. The effector cells for the ADCC assay were isolated from heparinized human peripheral blood. Mononuclear cells were obtained by flotation sedimentation using a Ficoll-Hypaque gradient according to Boyum (12) . After this treatment, phagocytic cells were removed by incubation with Technicon lymphocyte separating reagent (containing carbonyl iron coated with poly-L-lysine) at 37°C for 30 min before passage through a magnetic field (Technicon Lymphocyte Separator, Tepchnicon Inst. Corp., Tarrytown, N. Y.).
The resulting cell population contained more than 98% lymphocytes (Wright staining), with greater than 95% viability as judged by trypan blue dye exclusion. The cells were washed three times in TCM before use. Cell counts were made with a Coulter Counter Model ZB1 (Coulter Electronics Inc., Hialeah, Fla.). To assure accuracy, automatic counts were compared frequently with optical counts determined in a hemocytometer.
Preparation of antiserum. CRBC freshly obtained from a white leghorn chicken were placed in TH containing heparin. The cells were washed 3 times with TH-FCS and resuspended as a 10% suspension in saline. A New Zealand White rabbit was immunized intravenously with 1 ml of the 10% CRBC suspension biweekly for 3 wk. After a 2 mo rest, the rabbit was again immunized one time with 1 ml CRBC and bled by cardiac puncture 1 wk later. The anti-CRBC sera was decomplemented by heat inactivation (56'C for 30 min), aliquoted, and stored at -90°C until used.
ADCC. ADCC was measured by the procedure of Larsson et al. (13) , with modification.
For labeling with Na2Cr'104, CRBC were freshly obtained and washed as above. The cells were resuspended to a concentration of 1.5 X 108/ml in TH-FCS. 0.2 ml of a 1 mC/ml solution of Na2Cr'O4 was mixed with 0.2 ml of TH-FCS. 0.2 ml of the above CRBC suspension was then added and the mixture incubated for 1 h at 370C. The labeled cells were washed 3 times with TH-FCS, resuspended in 3 ml of the same buffer, and counted.
CRBC were diluted into TCM containing a 10E' dilution of rabbit anti-CRBC (for experimental group) or no antisera (control group) to yield 8 X 10' labeled CRBC/ml. t SLE compared to normal controls: A percent cytotoxicity P < 0.02.
14.7±3.9% whereas the increase in normal control lymphocytes was only 3.4±3.7% (Table I) . Moreover, even after this treatment, the mean percent cytotoxicity in SLE (35.3±+12.7) was still well below the mean of normal lymphocytes after pronase and overnight incubation (72.5+11.6%, P<0.01). In the PAN patients, the lymphocytes showed a more complete regeneration after treatment, with a mean increase in ADCC activity of 37.6±11.7%. The ADCC activity in PAN after treatmen.t (54.5±13.7%) did not differ significantly from controls (72.5±11.6%, P > 0.05 ).
Inhibition of ADCC by SLE sera. To evaluate the source of possible cell-bound blocking factors, we examined SLE sera for ability to inhibit the ADCC activity of normal human lymphocytes. Normal lymphocytes were preincubated for 1 h at 37°C in heat decomplemented human serum. When autologous or random normal serum was studied, less than 15% inhibition was observed (compared to the same lymphocytes in medium alone).
When sera from patients with active lupus were studied, the degree of inhibition of ADCC activity of normal lymphocytes ranged from 0-75% with a mean of 45.7±25% (Table II) . The sera of all SLE patients with significantly decreased ADCC showed blocking capability. Sera from a patient with PAN also showed inhibition of normal ADCC function. In this patient, the inhibitory capacity of the sera correlated inversely with the ADCC activity of the patient's lymphocytes. 2 Characterization of serum inhibitory factors. To determine whether immunoglobulins were responsible for the observed serum inhibition of normal ADCC, we selectively removed IgG or IgM from the sera of two SLE patients and one normal control by specific immunoadsorption. Removal of IgG from two SLE sera by incubation with Sepharose-goat anti-human IgG (Table  III) resulted in 16.3 and 7.3% inhibition, respectively. By contrast, removal of IgM by immunoadsorption resulted in a much higher inhibition (60.4 and 65.0%) that was similar to a control incubation with a normal goat globulin absorbent.
Sera from SLE patients and normal controls were fractionated on 10-35% linear sucrose density gradients.
Gradients were pooled into three major fractions representing 7S, 19S, and greater than 19S regions. The pooled fractions were dialysed against TCM and tested for their ability to inhibit normal lymphocytes in ADCC (Table IV ). In the five SLE patients tested, the 7S aFye, K., M. Becker, A. Theofilopoulos, H. Moutsopoulos, J. L. Feldmann, and N. Talal. (Table V) . DISCUSSION This study has demonstrated a significant decrease in ADCC activity in patients with active SLE, related in part to inhibitory serum factors. Two patients with PAN (17) . A significant increase in the ADCC capability of SLE lymphocytes was achieved by exposure of the cells to pronase followed by overnight incubation at 37°C and repeated washings. This partial regeneration of ADCC activity in SLE suggests that cell-bound blocking factors contribute to the decreased K cell function. Other authors have shown that incubation of SLE lymphocytes results in the release on inhibitory factors and restoration of mixed lymphocyte reactivity (18) . The inability to achieve complete restoration of ADCC activity in (21) by saturation of the K cell Fc receptors, specific for activated Fc of IgG. Inhibition of ADCC by the heavier fractions from SLE sera is probably due to immune complexes or aggregated IgG. A second mechanism for inhibition might involve IgG antibodies specific for cell surface antigens. These could bind to cells and inhibi,t ADCC acting as insoluble cellular immune complexes. Such a mechanism for inhibiting ADCC has been demonstrated in mice (22) . The inhibition of normal lymphocyte ADCC activity by 7S fractions of SLE sera was probably due to the presence of antilymphocyte antibodies of the IgG class. Such antibodies are known to exist in SLE (23) and are probably responsible for inhibition of the mixed lymphocy-te reaction. A third mechanism might involve antibodies specific for K cells which could sterically interfere with functional sites on these effector cells.
The reduction of ADCC activity in active SLE patients does not appear to be due to a coriticosteroid effect, since we found no correlation between the dose of prednisone and ADCC activity. Furthermore, inactive SLE patients receiving up to 30 mg/day prednisone had normal ADCC activity.
Inhibition of ADCC by sera containing immune complexes may be a useful assay in patients with immune complex diseases. This was shown by examining SLE sera in periods of greater or lesser disease activity. In all cases, sera from patients in the more active phase of their disease showed greater inhibition of ADCC. Thus the inhibition of ADCC by patient's sera may be a useful guide to activity in immune complex related diseases.
